Collegium Pharmaceutical, Inc. reported $808M of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $808M (to Q2 2026). Net income: $48M, trailing twelve months to Q2 2026. Free cash flow: $328M, trailing twelve months to Q2 2026. Operating margin: 19%, trailing twelve months to Q2 2026.

COLLCollegium Pharmaceutical, Inc.

Healthcare

$22.06-38% 1Y

$22.06

$21.8552 weeks$49.84

COLL as reported

Collegium Pharmaceutical, Inc. reported $808M of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed.

$808M

Revenue, trailing twelve months · to Q2 2026 · +14% against the twelve months before

Net income: $48M
Net income · +32% year on year · trailing twelve months to Q2 2026
Free cash flow: $328M
Free cash flow · +63% year on year · trailing twelve months to Q2 2026
Operating margin: 19%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for COLL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$808M	+14%	Q2 2026
Net income	$48M	+32%	Q2 2026
EPS	$1.24	+19%	Q2 2026
Gross margin	60%	n/a	Q2 2026
Operating margin	19%	n/a	Q2 2026
Net margin	5.8%	n/a	Q2 2026
ROE	20%	n/a	Q2 2026
ROA	3.6%	n/a	Q2 2026
ROIC	25%	n/a	Q4 2019 · 26 quarters behind
Free cash flow	$328M	+63%	Q2 2026
P/E	17.8	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.